Key Points
- Insider sale: Karen Foster sold 415 shares on November 25 at an average price of $26.74 for $11,097, and still owns 192,838 shares — a 0.21% reduction in her position (valued about $5.16M).
- BioLife shares recently traded around $26.50 with a 50‑day SMA of $26.46 and 200‑day SMA of $24.26; the company has a market cap of $1.28 billion and a negative P/E of -221.15.
- Analyst and institutional backdrop: consensus rating is a Moderate Buy with an average price target of $31.20, and institutional ownership is very high at 93.24% with firms like RBC substantially increasing positions.
BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Karen Foster sold 415 shares of the company's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $26.74, for a total value of $11,097.10. Following the completion of the sale, the insider owned 192,838 shares in the company, valued at $5,156,488.12. This represents a 0.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
BioLife Solutions Price Performance
Shares of BioLife Solutions stock opened at $26.54 on Friday. The business has a fifty day simple moving average of $26.46 and a two-hundred day simple moving average of $24.26. The company has a market capitalization of $1.28 billion, a price-to-earnings ratio of -221.15 and a beta of 1.97. BioLife Solutions, Inc. has a 1 year low of $19.10 and a 1 year high of $29.62.
Institutional Trading of BioLife Solutions
Several large investors have recently modified their holdings of the stock. Comerica Bank grew its stake in BioLife Solutions by 5.2% during the first quarter. Comerica Bank now owns 15,024 shares of the medical equipment provider's stock worth $343,000 after buying an additional 746 shares in the last quarter. Forum Private Client Group LLC acquired a new stake in shares of BioLife Solutions during the 2nd quarter worth approximately $232,000. Royal Bank of Canada boosted its position in shares of BioLife Solutions by 762.8% during the 1st quarter. Royal Bank of Canada now owns 698,251 shares of the medical equipment provider's stock worth $15,948,000 after acquiring an additional 617,320 shares in the last quarter. State of Alaska Department of Revenue increased its stake in BioLife Solutions by 10.2% in the second quarter. State of Alaska Department of Revenue now owns 22,096 shares of the medical equipment provider's stock valued at $475,000 after acquiring an additional 2,048 shares during the last quarter. Finally, Raymond James Financial Inc. raised its position in BioLife Solutions by 12.7% during the first quarter. Raymond James Financial Inc. now owns 897,421 shares of the medical equipment provider's stock valued at $20,497,000 after purchasing an additional 101,423 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
BLFS has been the topic of several research analyst reports. Wall Street Zen raised shares of BioLife Solutions from a "hold" rating to a "buy" rating in a report on Saturday, November 22nd. HC Wainwright reiterated a "buy" rating and set a $32.00 target price on shares of BioLife Solutions in a research note on Monday. Zacks Research upgraded BioLife Solutions from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 7th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of BioLife Solutions in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of "Moderate Buy" and an average price target of $31.20.
Read Our Latest Stock Report on BLFS
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
